No Data
No Data
Shaanxi Panlong Pharmaceutical (002864.SZ): Has accumulated repurchased 0.35% of shares.
On August 1st, Gelonhui reported that as of the close of July 31, 2024, Shaanxi Panlong Pharmaceutical (002864.SZ) had repurchased a total of 373,200 shares of the company's stock through its own funds using a repurchase dedicated securities account in a centralized bidding manner, accounting for 0.35% of the company's total share capital. The highest price was 27.81 yuan/share, the lowest price was 25.71 yuan/share, and the total amount paid was RMB 9.9943 million (excluding transaction costs).
Shaanxi Panlong Pharmaceutical (002864.SZ) was awarded as a green factory.
On July 10th, Gelunhui announced that Shaanxi Panlong Pharmaceutical (002864.SZ) has released their fifth batch of names for green manufacturing improvement to promote carbon neutrality and peak of the industrial sector. On July 8th, 2024, the Shaanxi Provincial Department of Industry and Information Technology issued a notice (Shaan Gongxin Issue [2024] No. 187) about publishing the fifth batch list of green manufacturing in Shaanxi Province. They evaluated applications from the unit, third-party evaluation institutions, recommendations from the local industry and information technology departments, expert reviews and assessments, online publicity, departmental conferences, and other processes. Shaanxi Panlong Pharmaceutical Group Co., Ltd is one of the groups on the list.
Shaanxi Panlong Pharmaceutical (002864.SZ): The main product Panlong Seven Tablets has almost no price difference between in-hospital and out-hospital sales.
On June 20, 2024, Shaanxi Panlong Pharmaceutical (002864.SZ) held a roadshow activity. When asked about the price difference between their products sold in and out of the hospital, the company replied that there is basically no difference in the price of their flagship product, Panlong Seven, sold both in and out of the hospital.
Shaanxi Panlong Pharmaceutical (002864.SZ) is actively promoting the construction of the production line for traditional Chinese medicine formula particles, and is expected to be completed and put into production in the second half of the year.
On June 20, 2024, Shaanxi Panlong Pharmaceutical (002864.SZ) held a roadshow event to discuss the progress of the development of traditional Chinese medicine formula granules and transdermal drug patches. The company replied that it is actively promoting the construction of the production line for traditional Chinese medicine formula granules and expects to complete it in the second half of the year. While accelerating the construction of the production line, the company is also rapidly intensifying the development and filing work of traditional Chinese medicine formula granules. At present, the research and development work of the company's high-barrier transdermal drug delivery system platform construction project is also proceeding in an orderly manner, and there will be milestone progress in the later stage.
Shaanxi Panlong Pharmaceutical (002864.SZ): Repurchased 100,500 shares for a total of 2.7418 million yuan for the first time.
On June 6th, Gelonhui reported that Shaanxi Panlong Pharmaceutical (002864.SZ) announced the first use of its own funds through the share repurchase special securities account to repurchase 100,500 shares of the company's stock through centralized bidding on June 6th, 2024, accounting for 0.0946% of the total share capital of the company. The highest fill price was 27.50 yuan/share, the lowest fill price was 27.01 yuan/share, and the fill amount was 2.7418 million yuan (excluding transaction costs).
There's A Lot To Like About Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Upcoming CN¥0.22 Dividend
No Data